These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17196702)

  • 21. [Me too's and generics].
    Gysling E
    Praxis (Bern 1994); 1999 Apr; 88(16):709-12. PubMed ID: 10355336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Making medicines safe.
    Videau JY
    Bull World Health Organ; 2001; 79(2):87. PubMed ID: 11242826
    [No Abstract]   [Full Text] [Related]  

  • 23. ACOG Committee Opinion No. 375: Brand versus generic oral contraceptives.
    Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists
    Obstet Gynecol; 2007 Aug; 110(2 Pt 1):447-8. PubMed ID: 17666623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concerns about the safety of obesity agents from a manufacturing perspective.
    Kanfer I
    Postgrad Med; 2008 Jul; 120(2):42-5. PubMed ID: 18654067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of generic drugs in Spain.
    García Alonso F
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():3. PubMed ID: 9800719
    [No Abstract]   [Full Text] [Related]  

  • 27. Quality of generic ophthalmic drugs.
    Novack GD
    Ocul Surf; 2013 Jan; 11(1):54-6. PubMed ID: 23321360
    [No Abstract]   [Full Text] [Related]  

  • 28. Development of generic low molecular weight heparins: a perspective.
    Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comments on generic antibiotics].
    Levêque D; Gourieux B
    Med Mal Infect; 2013 Jan; 43(1):35-6. PubMed ID: 23287656
    [No Abstract]   [Full Text] [Related]  

  • 30. The end of the beginning?
    Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
    [No Abstract]   [Full Text] [Related]  

  • 31. Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity.
    Schellekens H
    Eur J Clin Invest; 2004 Dec; 34(12):797-9. PubMed ID: 15606720
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin.
    Lambert PA; Conway BR
    J Chemother; 2003 Aug; 15(4):357-68. PubMed ID: 12962364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic drugs. Save money--but is there a cost?
    Roberts SS
    Diabetes Forecast; 2002 Nov; 55(11):51-3. PubMed ID: 14768605
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug companies lobby against generic versions of biologics.
    Tucker ME
    BMJ; 2013 Feb; 346():f740. PubMed ID: 23381589
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
    Rascati KL; Richards KM; Johnsrud MT; Mann TA
    Pharmacotherapy; 2009 Jul; 29(7):769-74. PubMed ID: 19558250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M
    Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
    Palylyk-Colwell E; Jamali F; Dryden W; Friesen E; Koven S; Mohamed I; Osmond B; Alessi-Severini S; Sheldon L; Sheldon R; Tam Y; Tsuyuki R; Zhanel G
    J Pharm Pharm Sci; 1998; 1(1):2-7. PubMed ID: 10942966
    [No Abstract]   [Full Text] [Related]  

  • 38. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Generics as therapeutic resources].
    Riverro-Serrano O; Juan-Lopez M; Lerdo-de Tejada F; Montoya-Cabrera MA; Camacho-Solís R; Valenzuela-Gomez Gallardo F; Lifshitz A; Gamboa-Marrufo J; Martínez-Domínguez M
    Gac Med Mex; 1998; 134(2):169-206. PubMed ID: 9618996
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparative testing and pharmacovigilance of biosimilars.
    Locatelli F; Roger S
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.